A citation-based method for searching scientific literature

Laura Cortesi, Bruna Baldassarri, Stefano Ferretti, Elisabetta Razzaboni, Mariangela Bella, Lauro Bucchi, Debora Canuti, Pierandrea De Iaco, Giorgio De Santis, Fabio Falcini, Vania Galli, Lea Godino, Maurizio Leoni, Anna Myriam Perrone, Marco Pignatti, Gianni Saguatti, Donatella Santini, Priscilla Sassoli de'Bianchi, Federica Sebastiani, Mario Taffurelli, Giovanni Tazzioli, Daniela Turchetti, Claudio Zamagni, Carlo Naldoni. Cancer Med 2020
Times Cited: 8

List of co-cited articles
5 articles co-cited >1

Times Cited
  Times     Co-cited

Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?
Laura Cortesi, Barbara Canossi, Rachele Battista, Annarita Pecchi, Antonella Drago, Chiara Dal Molin, Angela Toss, Elisabetta De Matteis, Isabella Marchi, Pietro Torricelli,[...]. Int J Cancer 2019

Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience.
Laura Cortesi, Daniela Turchetti, Isabella Marchi, Antonella Fracca, Barbara Canossi, Battista Rachele, Ruscelli Silvia, Pecchi Anna Rita, Torricelli Pietro, Federico Massimo. BMC Cancer 2006

Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
Adam N Rosenthal, Lindsay Fraser, Ranjit Manchanda, Philip Badman, Susan Philpott, Jessica Mozersky, Richard Hadwin, Fay H Cafferty, Elizabeth Benjamin, Naveena Singh,[...]. J Clin Oncol 2013

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017

Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy.
Laura Ottini, Valentina Silvestri, Piera Rizzolo, Mario Falchetti, Ines Zanna, Calogero Saieva, Giovanna Masala, Simonetta Bianchi, Siranoush Manoukian, Monica Barile,[...]. Breast Cancer Res Treat 2012

Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.
Ian J Seymour, Silvia Casadei, Valentina Zampiga, Simonetta Rosato, Rita Danesi, Emanuela Scarpi, Fabio Falcini, Miria Strada, Nori Morini, Carlo Naldoni,[...]. Breast Cancer Res Treat 2008

The Role of Genetic Testing in Patients With Breast Cancer: A Review.
Olivia M Valencia, Selyne E Samuel, Rebecca K Viscusi, Taylor S Riall, Leigh A Neumayer, Hassan Aziz. JAMA Surg 2017

American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
Mark E Robson, Courtney D Storm, Jeffrey Weitzel, Dana S Wollins, Kenneth Offit. J Clin Oncol 2010

Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.
E Amir, D G Evans, A Shenton, F Lalloo, A Moran, C Boggis, M Wilson, A Howell. J Med Genet 2003

Breast cancer genetics in young women: What do we know?
Liliana Gómez-Flores-Ramos, Rosa María Álvarez-Gómez, Cynthia Villarreal-Garza, Talia Wegman-Ostrosky, Alejandro Mohar. Mutat Res Rev Mutat Res 2017

Cancer genetic risk assessment for individuals at risk of familial breast cancer.
Jennifer S Hilgart, Bernadette Coles, Rachel Iredale. Cochrane Database Syst Rev 2012

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002

BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer.
D Turchetti, L Cortesi, M Federico, C Bertoni, L Mangone, S Ferrari, V Silingardi. Eur J Cancer 2000

Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
Elvira D'Andrea, Carolina Marzuillo, Corrado De Vito, Marco Di Marco, Erica Pitini, Maria Rosaria Vacchio, Paolo Villari. Genet Med 2016

Young Women's Perceptions Regarding Communication with Healthcare Providers About Breast Cancer, Risk, and Prevention.
Natasha Buchanan Lunsford, Karena F Sapsis, Betsy Smither, Jennifer Reynolds, Ben Wilburn, Temeika Fairley. J Womens Health (Larchmt) 2018

Multiple primary cancers as a guide to heritability.
Cezary Cybulski, Safia Nazarali, Steven A Narod. Int J Cancer 2014

Hereditary cancer syndromes.
T S Frank. Arch Pathol Lab Med 2001

Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
Devin M Cox, Katherine L Nelson, Meera Clytone, Debra L Collins. Mol Genet Genomic Med 2018

Identification of hereditary cancer in the general population: development and validation of a screening questionnaire for obtaining the family history of cancer.
Natalia Campacci, Juliana O de Lima, André L Carvalho, Rodrigo D Michelli, Rafael Haikel, Edmundo Mauad, Danilo V Viana, Matias E Melendez, Fabiana de L Vazquez, Cleyton Zanardo,[...]. Cancer Med 2017

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Ranjit Manchanda, Shreeya Patel, Vladimir S Gordeev, Antonis C Antoniou, Shantel Smith, Andrew Lee, John L Hopper, Robert J MacInnis, Clare Turnbull, Susan J Ramus,[...]. J Natl Cancer Inst 2018

Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
N Jewel Samadder, Karthik V Giridhar, Noemi Baffy, Douglas Riegert-Johnson, Fergus J Couch. Mayo Clin Proc 2019

Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
L S Friedman, S A Gayther, T Kurosaki, D Gordon, B Noble, G Casey, B A Ponder, H Anton-Culver. Am J Hum Genet 1997

Compliance with professional guidelines with reference to familial cancer services.
Gaenor Kyne, Susannah Maxwell, Kate Brameld, Katrina Harrison, Jack Goldblatt, Peter O'Leary. Aust N Z J Public Health 2011

Clinical/genetic features in hereditary breast cancer.
H T Lynch, P Watson, T A Conway, J F Lynch. Breast Cancer Res Treat 1990

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Mark Robson, Kathryn J Ruddy, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Wei Li, Nadine Tung, Anne Armstrong,[...]. Eur J Cancer 2019

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.
George Somlo, Paul H Frankel, Banu K Arun, Cynthia X Ma, Agustin A Garcia, Tessa Cigler, Leah V Cream, Harold A Harvey, Joseph A Sparano, Rita Nanda,[...]. Clin Cancer Res 2017

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
Nadine M Tung, Judy C Boughey, Lori J Pierce, Mark E Robson, Isabelle Bedrosian, Jill R Dietz, Anthony Dragun, Judith Balmana Gelpi, Erin W Hofstatter, Claudine J Isaacs,[...]. J Clin Oncol 2020

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Nicholas C Turner, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A Mina, Judith Balmaña, Peter A Fasching, Sara A Hurvitz,[...]. Clin Cancer Res 2019

Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results.
Francesco Sardanelli, Franca Podo, Filippo Santoro, Siranoush Manoukian, Silvana Bergonzi, Giovanna Trecate, Daniele Vergnaghi, Massimo Federico, Laura Cortesi, Stefano Corcione,[...]. Invest Radiol 2011

USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
Padma Sheila Rajagopal, Sarah Nielsen, Olufunmilayo I Olopade. JAMA Netw Open 2019

Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
Theresa L Werner, Jasgit Sachdev, Elizabeth M Swisher, Martin Gutierrez, Muaiad Kittaneh, Mark N Stein, Hao Xiong, Martin Dunbar, Danielle Sullivan, Philip Komarnitsky,[...]. Cancer Med 2018

A systematic review of the international prevalence of BRCA mutation in breast cancer.
Nigel Armstrong, Steve Ryder, Carol Forbes, Janine Ross, Ruben Gw Quek. Clin Epidemiol 2019

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Véronique Diéras, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, Igor Bondarenko, Mario Campone, Erik H Jakobsen,[...]. Lancet Oncol 2020

A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women.
L Cortesi, E Razzaboni, A Toss, E De Matteis, I Marchi, V Medici, G Tazzioli, A Andreotti, G De Santis, M Pignatti,[...]. Ann Oncol 2014

Preoperative genetic testing affects surgical decision making in breast cancer patients.
Elizabeth Lokich, Ashley Stuckey, Christina Raker, Jennifer Scalia Wilbur, Jessica Laprise, Jennifer Gass. Gynecol Oncol 2014

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
M E Thompson, R A Jensen, P S Obermiller, D L Page, J T Holt. Nat Genet 1995

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Nadine M Tung, Mark E Robson, Steffen Ventz, Cesar A Santa-Maria, Rita Nanda, Paul K Marcom, Payal D Shah, Tarah J Ballinger, Eddy S Yang, Shaveta Vinayak,[...]. J Clin Oncol 2020

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.